Barnett AH, et al. - Researchers evaluated the long-term cost-effectiveness of switching from sitagliptin to liraglutide in patients with type 2 diabetes in the UK. They used the IQVIA CORE Diabetes Model Version 8.5+ to project costs and clinical outcomes over patients' lifetimes. From the LIRA-SWITCH trial, baseline cohort characteristics and treatment effects were derived. In patients with poor glycaemic control, switching from sitagliptin 100 mg to liraglutide 1.8 mg was projected to improve clinical outcomes and was likely to be considered cost-effective in the UK setting and, therefore, a good use of limited NHS resources.